Current Status of the Strecker Stent

Strecker, Ernst-Peter; Hagen, B; Liermann, D.; Boos, Irene; Kuhn, F.-P.; Reifart, Nicolaus; Théron, J.; Betz, E; Gabelmann, Andreas; Haberstroh, Jörg; Freudenberg, Nikolaus; Kunnen, Jan

doi:10.1016/s0733-8651(18)30084-5

Cited by 18 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various designs of such therapeutic devices are currently being used for percutaneous treatment and prevention of residual stenosis following angioplasty. Referring to mid-and long-term patency rates, similar results with a 2-year patency of approximately 84 % have been achieved after Wall, Palmaz, or Strecker stent placement in pelvic arteries [2,3,4]. For these metallic stents biocompatibility is satisfactory without showing differences due to differences concerning stent design, mechanical properAbstract The aim of this study was to determine flow characteristics and pressure gradients of different balloon-and self-expandable stents in an in vitro flow-model.…”

mentioning

confidence: 81%

Flow patterns from metallic vascular endoprostheses: in vitro results

Müller‐Hülsbeck¹,

Grimm²,

Jahnke³

et al. 2001

European Radiology

View full text Add to dashboard Cite

The aim of this study was to determine flow characteristics and pressure gradients of different balloon- and self-expandable stents in an in vitro flow-model. Seven vascular stents (Bridge, Cragg, Memotherm, Palmaz PS 784, Sinus, Symphony, Wallstent), equal in length (60 mm) and diameter (10 mm), were deployed in a closed flow model. The inner diameter of the tube measured 9 mm. Flow at 1.5 and 6 l/min was applied. Flow patterns were visualized by anionic particles illuminated with two helium-neon lasers. Late laminary flow characteristics and pre-/post-stent pressure gradients were determined in either expanded stent, 25 and 50% tube stenosis. Stent implantation induced a decrease of laminary flow when compared with an unstented tube with and without concentric 25% stenosis (p < 0.01) at all flow rates and an increase of pressure gradients when compared with an unstented tube for a flow rate of 6 l/min and all stenoses (p < 0.01). At 1.5 l/min most stents revealed no significant change of pressure gradient, the highest gradient measured 4.0 mmHg. Sinus permitted maximum (expanded: 82.1% and 76.9% at 25% stenosis at 1.5 l/min; p < 0.01) and Palmaz minimum of laminary flow at all flow rates and stenoses (70.2 and 52.4% at 25% stenosis at 1.5 l/min; p < 0.01). At 6 l/min, when completely expanded, Sinus is equal to Bridge and Memotherm; in 25% stenosis Sinus is equal to Bridge, Memotherm, and additionally to Cragg and Wall. None of the endoprostheses revealed laminary flow at 50% stenosis. Inadequate stent deployment bears the risk of creating less laminary flow and pressure gradients. Since flow disturbances and pressure gradients may influence neointimal hyperplasia, stent design and completeness of stent expansion are important factors regarding the appearance of thrombus formation and postinterventional restenosis.

show abstract

mentioning

confidence: 81%

Flow patterns from metallic vascular endoprostheses: in vitro results

Müller‐Hülsbeck¹,

Grimm²,

Jahnke³

et al. 2001

European Radiology

View full text Add to dashboard Cite

show abstract

“…As a result of an earlier work performed by Machan et al [110], which suggested that the chemotherapeutic agent Taxol (paclitaxel, an angiogenesis inhibitor) may be effective in preventing tissue hyperplasia, Manifold et al [111] carried out a prospective study to assess whether Ultraflex stents coated with paclitaxel were resistant to tumor ingrowth and obtained promising results. The use of a polyactide covering membrane, which is biocompatible and biodegradable so that an incorporated drug is eluted, has been investigated on tantalum arterial stents [112]. Early results of studies of the use of angiogenesis inhibitor coated metal stents in porcine bile ducts to prevent benign reactive overgrowth have been encouraging [113].…”

Section: Future Developmentsmentioning

confidence: 99%

Stenting in Esophageal Strictures

Petruzziello

Costamagna²

2002

Dig Dis

View full text Add to dashboard Cite

The interventional management of esophageal strictures remains, to date, an important clinical challenge. Stenting is probably the best palliation modality in patients with incurable esophagogastric carcinoma. Conversely, the use of esophageal stents is still relatively uncommon for the treatment of refractory benign strictures. In the last few years, several new stents have become available as a result of significant advances that have been made in terms of design and materials. This review focuses on the endoscopic use of esophageal stents in malignant and benign esophageal strictures, revisiting the different types of expandable stents presently available, the techniques, the results, and the complications of stent insertion and giving some practical advices. Future developments in the field of esophageal stenting are also discussed.

show abstract

“…been investigated on tantalum arterial stents. 47 Early results of studies of the use of angiogenesis inhibitorcoated metallic stents in porcine bile ducts to prevent benign reactive overgrowth have been encouraging. 48 The use of radiation therapy before and after stent implantation 49,50 may limit neointimal growth and improve long-term stent patency.…”

Section: Esophacoil-srmentioning

confidence: 99%